• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    NICE says yes to GSK`s Cabenuva, new option for HIV patients

    FIERCEPHARMA

    ViiV sees first global approval of Cabenuva in Canada

    PHARMATIMES

    FDA Confirms Paragraph IV Patent Challenge of Odefsey 208351 (Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate )Tablets

    FDA

    FDA slams GSK`s monthly HIV injectable with CRL, citing manufacturing issues

    ENDPTS

    J&J-backed AIDS film picked up by Verizon Media

    FIERCE PHARMA

    Prescription med: new or extended uses, new combinations of registered medicines

    TGA

    Fresh off its Juluca approval, GSK beefs up trials of long-acting HIV duo

    FIERCE PHARMA

    ViiV’s long-acting two-drug HIV regimen hits targets

    PHARMA TIMES

    With two-drug combo data, GSK primes for an HIV market-share steal

    FIERCE PHARMA

    Gilead`s latest HIV cocktail wins FDA approval with a blockbuster pedigree

    FIERCE BIOTECH

    J&J and ViiV line up Phase III trials for a long-acting HIV treatment

    FIERCE BIOTECH

    ViiV to Progress Collaboration with Janssen to Develop First Long-acting

    PR NEWS WIRE

    ViiV Announces Positive Results from a Study for HIV Maintenance Therapy

    PR NEWS WIRE

    Gilead`s low-dose, high-impact HIV drug heads to the FDA

    SAN FRANSISCO BUSINESS TIMES

    Gilead Announces Amended Agreements with Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment

    BIOSPECTRUM ASIA

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.